Nao Yoshida-Sakai

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 8

Top Topics

Acute Myeloid Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

Cancer research communications

Annals of hematology

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Tatsuro Watanabe, Yuta Yamamoto, Yuki Kurahashi, Kazunori Kawazoe, Keisuke Kidoguch, Hiroshi Ureshino, Kazuharu Kamachi, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Hideaki Nakamura, Seiji Okada, Eisaburo Sueoka, Shinya Kimura
Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells. Blood advances (2024)
Tatsuro Watanabe, Yuta Yamamoto, Yuki Kurahashi, Kazunori Kawazoe, Keisuke Kidoguch, Hiroshi Ureshino, Kazuharu Kamachi, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Hideaki Nakamura, Seiji Okada, Eisaburo Sueoka, Shinya Kimura
Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells. Blood advances 8 (6) (2024)
Tatsuro Watanabe, Yuta Yamamoto, Yuki Kurahashi, Kazunori Kawazoe, Keisuke Kidoguch, Hiroshi Ureshino, Kazuharu Kamachi, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Hideaki Nakamura, Seiji Okada, Eisaburo Sueoka, Shinya Kimura
Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells. Blood advances 8 (6) (2024)
Kazuharu Kamachi, Hiroshi Ureshino, Tatsuro Watanabe, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Kazunori Kawazoe, Toshimi Hoshiko, Yuta Yamamoto, Yuki Kurahashi, Shinya Kimura
Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia. Cancer research communications 3 (2) (2023)
Kazuharu Kamachi, Hiroshi Ureshino, Tatsuro Watanabe, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Kazunori Kawazoe, Toshimi Hoshiko, Yuta Yamamoto, Yuki Kurahashi, Shinya Kimura
Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia. Cancer research communications 3 (2) (2023)
Yuki Kurahashi, Tatsuro Watanabe, Yuta Yamamoto, Hiroshi Ureshino, Kazuharu Kamachi, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Satoshi Yamashita, Naoko Hattori, Hideaki Nakamura, Atsushi Kawaguchi, Toshikazu Ushijima, Eisaburo Sueoka, Shinya Kimura
Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL. Blood advances (2022)
Nao Yoshida-Sakai, Kensuke Oe, Yoshizo Kimura, Hiroshi Ureshino, Keita Nomiyama, Michitoshi Hashiguchi, Hiroto Jojima, Yutaka Imamura, Koichi Ohshima, Takashi Okamura
Coexistence of gastric and pulmonary MALT lymphoma and a clonally related, disseminated large B cell lymphoma with conspicuous angiotropism. Annals of hematology 101 (6) (2022)
Hiroshi Ureshino, Yuki Kurahashi, Tatsuro Watanabe, Satoshi Yamashita, Kazuharu Kamachi, Yuta Yamamoto, Yuki Fukuda-Kurahashi, Nao Yoshida-Sakai, Naoko Hattori, Yoshihiro Hayashi, Atsushi Kawaguchi, Kaoru Tohyama, Seiji Okada, Hironori Harada, Toshikazu Ushijima, Shinya Kimura
Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects. Molecular cancer therapeutics 20 (8) (2021)